Latest Updates
-
Chana Masala Recipe: Experience Dhaba Style Authentic Taste -
Struggling With Oily Skin This Summer? Simple Tips to Keep Shine Under Control -
Garlic Bread Recipe: The Cheesy Bakery Style Trick You Need -
Soha Ali Khan Swears By This ‘Gentle Game-Changer’ Lemon Drink for Gut Health: Full Recipe Inside -
World Health Day 2026: You’re Not As Healthy As You Think—Here’s Why -
One Pot Easy Lunch Recipe: Flavorful Veg Pulao -
Karan Aujla India Tour Controversy: Lucknow and Ludhiana Shows Cancelled—What Went Wrong? -
Kissing Disease Linked to 3x Higher Risk of Multiple Sclerosis: What You Should Know -
Feeling Drained in the Heat? 10 Healthy Drinks to Sip This Summer -
Happy Birthday Rashmika Mandanna: Steal Her White Looks For Easter 2026 Festive Parties And Celebrations
Adult Stem Cells To Treat Autoimmune Diseases
{image- www.boldsky.com} Washington: Adult aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic harvested from either blood or bone marrow might help in the treatment of a wide range of autoimmune diseases and heart disease, according to a research review conducted by scientists at the Northwestern University Feinberg School of Medicine.
There are two types of aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic, embryonic aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic and adult aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic. Human embryonic aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic are harvested from embryos four to five days after fertilization. Adult aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic are located in tissues throughout the body and provide a reservoir for replacement of damaged or aging cells.
Dr. Richard K. Burt, of the Northwestern University Feinberg School of Medicine, and colleagues examined hundreds of studies of blood- or bone marrow derived aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic that were conducted between January 1997 and December 2007 -- 323 assessed feasibility and toxicity, and 69 looked at patient outcomes.
The review found that in 26 studies involving a total of 854 patients with autoimmune diseases there was a treatment-related death rate of less than one percent (2/220 patients) for nonmyeloablative (not causing bone marrow suppression), less than two percent (3/197) for dose-reduced myeloablative, and 13 percent (13/100) for intense myeloablative regimens, i.e., those including total body irradiation or high-dose busulfan, a drug used in the treatment of some types of chronic leukemia.
"While all trials performed during the inflammatory stage of autoimmune disease suggested that transplantation of hematopoietic [formation of blood or blood cells] aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic (HSCs) may have a potent disease-remitting effect, remission duration remains unclear, and no randomized trials have been published," the researchers said.
In 17 studies of 1,002 patients with cardiovascular diseases, 16 studies of 493 patients with chronic coronary artery disease, and three meta-analyses, there was evidence suggesting that adult stem cell transplantation might help lead to modest improvements in cardiac function among people with coronary artery disease.
"aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic harvested from blood or marrow, whether administered as purified HSCs or mesenchymal [cells that develop into connective tissue, blood vessels and lymphatic tissue] aging,autoimmune diseases,blood,bone,death,feinberg school,heart disease,nonmyeloablative,stem cells,toxic or as an unmanipulated or unpurified product can, under appropriate conditions in select patients, provide disease-ameliorating effects in some autoimmune diseases and cardiovascular disorders," the researchers said.
Clinical trials are needed to determine the most appropriate cell type, dose, method, timing of delivery, and adverse effects of adult HSCs for these and other nonmalignant disorders," the researchers added.
The review is published in the February 27 issue of JAMA.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











